Mizuho Boosts Exact Sciences Corp. (EXAS) Price Target to $15.00

BTIG Research reiterated a “buy” rating on shares of Exact Sciences Corp.in a research note on Tuesday, May 10th. Exact Sciences Corp.’s revenue was up 161.7% compared to the same quarter a year ago. The company recorded a trading capacity of 1.71 million shares below its three months average daily volume of 1.72 million shares.

EXACT Sciences fared well in the June quarter, posting results that handily beat the consensus estimates.

Exact Sciences Corporation’s (EXAS) witnessed a gain of 3.76% in recent trading period with closing price of $ 16.82. Now the stock has been rated as “Buy” from 0 Analysts. Finally, Geode Capital Management LLC boosted its position in Exact Sciences Corp.by 4.5% in the first quarter. The Company has also granted the underwriters an option to purchase up to 1,050,000 additional shares. Finally, Smith Asset Management Group LP bought a new stake in Exact Sciences Corp. during the second quarter worth approximately $237,000. The stock hit the peak level of one year at $50.01 and touched the minimum level of $35.56. 3,684,361 shares of the company’s stock were exchanged.

The company’s weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, feeble growth in its earnings per share, generally disappointing historical performance in the stock itself and weak operating cash flow.

10/06/2015 – EXACT Sciences Corporation had its “neutral” rating reiterated by analysts at Wedbush.

While Looking at the Earnings Estimates of the company, The Average Earnings Estimate for the Current Fiscal quarter is measured as -$0.44 by 13 analysts.

During the most recent trading day, the stock’s price shifted up +270.88% from its 52-week low and -29.99% lower from its 52-week high. Exact Sciences Corporation (EXAS) released that upsizing and pricing of its before reported underwritten public offering of ordinary stock.

Several other research analysts have also weighed in on EXAS. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company.

EXACT Sciences Corporation (NASDAQ:EXAS) has been evaluated and allotted ratings by 9 brokerages over a period of 12 months. The stock has received “HOLD” rating after consensus analysis from analysts.

Maneesh Arora, the COO of Exact Sciences Corp, made a sale of 7,359 shares of the company, with a total value $109,060 U.S Dollars, based on an avg price of $14.8 per each share. When considering if perhaps the stock is under or overvalued, the average price target is $13.50 which is -18.9% under where the stock opened today.

Exact Sciences Corp. is making more stock available to the public to raise money for marketing Cologuard, the Madison company’s test for colorectal cancer. The stock now has Price to Sales (P/S) value of 32.71 where Price to Book (P/B) value stands at 5.68.EXAS is now showing ROA (Return on Assets) value of -50.8% where ROE (Return on Equity) is -56.4%. The Company’s product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline.